Zoll Medical's defibrillator gets US clearance:
This article was originally published in Clinica
Burlington, Massachusetts-based Zoll Medical has received US FDA 510(k) clearance for its Zoll M series defibrillator with end-tidal carbon dioxide (EtCO2) monitoring. The cardiac resuscitation device integrates a technology developed by Novametrix Medical Systems, called Capnostat, a solid-state sensor that monitors carbon dioxide and respiratory rate, pertinent to pacing and defibrillation. EtCO2 monitoring is the standard of care in hospital operating rooms, recovery areas, intensive care units and critical care units. The device can be used to assess patient airway integrity and proper endotracheal tube placement, the company said.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.